Skip to main content
Top
Published in: Rheumatology International 3/2007

01-01-2007 | Original Article

Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies

Authors: Sara Kashef, Mohammad Mehdi Ghaedian, Akbar Rajaee, Abbas Ghaderi

Published in: Rheumatology International | Issue 3/2007

Login to get access

Abstract

Dyslipoproteinemia is common in lupus patients. In this study, we investigated the pattern of dyslipoproteinemia in the course of active systemic lupus erythematosus (SLE) in possible association with anti-double-stranded DNA (anti-dsDNA) antibodies. Forty-six lupus patients under 45 years old who fulfilled the American College of Rheumatology revised criteria for the classification of SLE were selected. The exclusion criteria were renal failure, nephrotic syndrome, thyroid or liver disease, diabetes mellitus, obesity, pregnancy and taking drugs that induce dyslipidemia. Disease activity was measured by Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Comparison of the lipid profiles, between active and inactive groups determined high levels of serum TG and VLDL and low levels of serum HDL in active group in comparison with inactive group(P < 0.05). The results indicated that the levels of TG and VLDL were significantly elevated in the patients with positive anti-dsDNA (P < 0.05). Although, the mean of serum HDL levels was also lower in patients with positive anti-dsDNA, the difference was not significant. This pattern of dyslipoproteinemia in active SLE may be associated with the autoimmune mechanisms especially in relation to the presence of anti-dsDNA antibodies.
Literature
1.
go back to reference Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363PubMedCrossRef Formiga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R (2001) Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 10:359–363PubMedCrossRef
2.
go back to reference Ettinger WH, Goldberg AP, Appelbaum-Bowden D, Hazzard WR (1987) Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83:503–508PubMedCrossRef Ettinger WH, Goldberg AP, Appelbaum-Bowden D, Hazzard WR (1987) Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 83:503–508PubMedCrossRef
3.
go back to reference Petri M (2000) Detection of coronary artery disease and role of traditional risk factors in the Hopkins lupus Cohort. Lupus 9(3):170–175PubMedCrossRef Petri M (2000) Detection of coronary artery disease and role of traditional risk factors in the Hopkins lupus Cohort. Lupus 9(3):170–175PubMedCrossRef
4.
go back to reference Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264–1267PubMed Leong KH, Koh ET, Feng PH, Boey ML (1994) Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 21:1264–1267PubMed
5.
go back to reference Lahita RG, Rivkin E, Cavanagh I, Romano P (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566–1574PubMed Lahita RG, Rivkin E, Cavanagh I, Romano P (1993) Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 36:1566–1574PubMed
6.
go back to reference Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863PubMed Ilowite NT, Samuel P, Ginzler E, Jacobson MS (1988) Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum 31:859–863PubMed
7.
go back to reference Borba EF, Bonfá E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539PubMed Borba EF, Bonfá E (1997) Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 6:533–539PubMed
8.
go back to reference Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M (2002) Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957–2963PubMedCrossRef Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M (2002) Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 46:2957–2963PubMedCrossRef
9.
go back to reference Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277PubMed
10.
go back to reference Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Committee on prognosis studies in SLE. Derivation of the SLEDAI a: disease activity index for lupus patients. Arthritis Rheum 35:630–640PubMed Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Committee on prognosis studies in SLE. Derivation of the SLEDAI a: disease activity index for lupus patients. Arthritis Rheum 35:630–640PubMed
11.
go back to reference Warnick GR, Benderson J, Albers JJ (1982) Dextran sulfate–Mg2 + precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28:1379–1388PubMed Warnick GR, Benderson J, Albers JJ (1982) Dextran sulfate–Mg2 + precipitation procedure for quantitation of high-density lipoprotein cholesterol. Clin Chem 28:1379–1388PubMed
12.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin chem 18:499–502PubMed
13.
go back to reference Gharavi AV, Lockshin MD (1997) Antiphospholipid antibodies. In: Rose NR, Macario EC, Folds JD, et al (eds) manual of clinical laboratory, 5th edn, ASM press Immunology, Washington DC, pp 949–953 Gharavi AV, Lockshin MD (1997) Antiphospholipid antibodies. In: Rose NR, Macario EC, Folds JD, et al (eds) manual of clinical laboratory, 5th edn, ASM press Immunology, Washington DC, pp 949–953
14.
go back to reference Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J (2003) Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/ tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48:2533–2540PubMedCrossRef Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J (2003) Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/ tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 48:2533–2540PubMedCrossRef
15.
go back to reference Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS (1995) Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 22:1347–1351PubMed Ilowite NT, Copperman N, Leicht T, Kwong T, Jacobson MS (1995) Effects of dietary modification and fish oil supplementation on dyslipoproteinemia in pediatric systemic lupus erythematosus. J Rheumatol 22:1347–1351PubMed
16.
go back to reference Ginsberg HN (1990) Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am 19:211–228PubMed Ginsberg HN (1990) Lipoprotein physiology and its relationship to atherogenesis. Endocrinol Metab Clin North Am 19:211–228PubMed
17.
go back to reference Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron (2000) Metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033–1040PubMedCrossRef Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron (2000) Metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 43:1033–1040PubMedCrossRef
18.
go back to reference Beaumont JL, Berard M, Antonucci M, Delplanque B, Vranckx R (1997) Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia. Atherosclerosis 26:67–77CrossRef Beaumont JL, Berard M, Antonucci M, Delplanque B, Vranckx R (1997) Inhibition of lipoprotein lipase activity by a monoclonal immunoglobulin in autoimmune hyperlipidemia. Atherosclerosis 26:67–77CrossRef
19.
go back to reference Alverson DC, Chase HP (1977) Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91:72–75PubMedCrossRef Alverson DC, Chase HP (1977) Systemic lupus erythematosus in childhood presenting as hyperlipoproteinemia. J Pediatr 91:72–75PubMedCrossRef
20.
go back to reference Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686–2694PubMedCrossRef Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA (2002) Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 46:2686–2694PubMedCrossRef
21.
go back to reference Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K,Tonozuka N,Hayashi T, Umeda M (2001) Anti- apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 28:990–995PubMed Abe H, Tsuboi N, Suzuki S, Sakuraba H, Takanashi H, Tahara K,Tonozuka N,Hayashi T, Umeda M (2001) Anti- apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 28:990–995PubMed
22.
go back to reference Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG (1998) Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7:355–360PubMedCrossRef Dinu AR, Merrill JT, Shen C, Antonov IV, Myones BL, Lahita RG (1998) Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7:355–360PubMedCrossRef
23.
go back to reference Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391PubMed Lazarevic MB, Vitic J, Myones BL, Mladenovic V, Nanusevic N, Skosey JL, Swedler WI (1993) Antilipoprotein antibodies in rheumatoid arthritis. Semin Arthritis Rheum 22:385–391PubMed
24.
go back to reference Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC (1999) Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18:17–22PubMedCrossRef Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC (1999) Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18:17–22PubMedCrossRef
25.
go back to reference Semb H, Peterson J, Tavernier J, Olivecrona T (1987) Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol chem 262:8390–8394PubMed Semb H, Peterson J, Tavernier J, Olivecrona T (1987) Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J Biol chem 262:8390–8394PubMed
26.
go back to reference Beutler BA, Cerami A (1985) Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 135:3969–3971PubMed Beutler BA, Cerami A (1985) Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol 135:3969–3971PubMed
27.
go back to reference Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, Cantell K (1982) Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 2:68–73PubMed Ehnholm C, Aho K, Huttunen JK, Kostiainen E, Mattila K, Pakkarainen J, Cantell K (1982) Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 2:68–73PubMed
28.
go back to reference Kwiterovich PO Jr (1998) The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82:13Q–21QPubMedCrossRef Kwiterovich PO Jr (1998) The antiatherogenic role of high-density lipoprotein cholesterol. Am J Cardiol 82:13Q–21QPubMedCrossRef
29.
go back to reference Third report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III): final report. Circulation 106:3143–3420 Third report of the National Cholesterol Education Program (NCEP) (2002) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III): final report. Circulation 106:3143–3420
Metadata
Title
Dyslipoproteinemia during the active course of systemic lupus erythematosus in association with anti-double-stranded DNA (anti-dsDNA) antibodies
Authors
Sara Kashef
Mohammad Mehdi Ghaedian
Akbar Rajaee
Abbas Ghaderi
Publication date
01-01-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 3/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0195-3

Other articles of this Issue 3/2007

Rheumatology International 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.